The Impact of Carboxy Nitroxide Antioxidants on Irradiated Ataxia Telangiectasia Cells by Hosokawa, Kazuyuki et al.
Carboxy Nitroxide Antioxidants 1
The Impact of Carboxy Nitroxide Antioxidants on Irradiated 
Ataxia-Telangiectasia cells 
 
Kazuyuki Hosokawa1, Philip Chen2, Martin F. Lavin2,3 and Steven E. Bottle1 
 
1. Science Research Centre, Faculty of Science, Queensland University of Technology, Brisbane, 
Queensland, 4001, Australia 
2. The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston, Queensland, 4029, 
Australia 
3. Department of Surgery, University of Queensland, Brisbane, Australia 
 
Correspondence to:Dr Steven E. Bottle 
Research Program Leader 
Science Research Centre 
Faculty of Science 
Queensland University of Technology 
GPO Box 2434, Q 4001  Australia  
Email: s.bottle@qut.edu.au 
 
ABSTRACT 
Three water soluble carboxy nitroxide antioxidants, CTMIO (5-carboxy-
1,1,3,3-tetramethylisoindolin-2-yloxyl, 1), CTEMPO (4-carboxy-2,2,6,6-
tetramethylpiperidin-1-yloxyl, 2) and CPROXYL (3-carboxy-2,2,5,5-
tetramethylpyrrolidin-1-yloxyl, 3) show significant impact on the post irradiation 
survival rates of Ataxia Telangiectasia (A-T) cells compared to normal cells; an assay 
which represents a model for understanding the impact of ROS damage on the A-T 
phenotype. The effect of these antioxidants is much more significant than for vitamin 
E or Trolox (a water-soluble vitamin E analogue), studied using the same cell survival 
model. 
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INTRODUCTION 
  
Ataxia Telangiectasia (A-T) is an autosomal recessive, genetic childhood disease 
characterised by a pleiotropic phenotype which includes progressive cerebellar 
degeneration, immune dysfunction and genome instability [1,2]. Patients with this 
disorder are strongly pre-disposed towards cancer, being highly susceptible to 
ionising radiation and radiomimetic chemicals. Early characteristics of A-T are 
cerebellar ataxia (lack of muscle control) and telangiectases (dilated blood vessels). 
All children with A-T experience a steady degeneration, or lack of development, of 
their motor skills and balance systems. More than half the children with A-T do not 
reach their teens and survival to the twenties is rare. A-T affects up to 1:100,000 live 
births and there is currently no treatment for the disease. 
 
First described as a disease entity in 1957, the physiological and molecular 
basis of A-T remained unclear until the gene responsible was identified [3] and named 
Ataxia Telangiecstasia Mutated (ATM). The protein expressed by the ATM gene 
plays a key role in cellular responses to DNA damage and in the activation of cell 
cycle check points [4]. Recently, evidence has emerged that A-T cells exist under a 
constant state of oxidative stress with high levels of reactive oxygen species (ROS), 
which in turn may contribute to many of the degenerative processes observed in the 
disease [5,6]. In this context it has been suggested that the neuronal defects in A-T 
may arise as a consequence of oxidative stress for which there is some evidence in the 
cerebellum of Atm deficient mice [7-10].  With evidence of both reduced antioxidant 
capacity and the presence of high levels of oxidative stress in A-T cells, treatment of 
A-T patients with antioxidants should be of benefit.  However, although the use of 
natural antioxidants, such as vitamin E (alpha-tocopherol) and vitamin C (ascorbic 
acid), has been proposed as a potential treatment, there has been little evidence to 
support their efficacy [11], possibly because the bio-control mechanisms regulating 
these natural endogenous substances remain in place. Studies using alpha-lipoic acid 
[6] have shown decreased protein markers for oxidative stress in A-T cells, however 
complications with toxicity at the doses required to generate an effect has limited this 
approach.  
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One class of powerful antioxidants, the nitroxides, has not previously been 
investigated in this context.  Nitroxides are stable free radicals able to scavenge 
radicals and act as radical chain terminators [12].  Recently it has become clear that, 
through one electron redox cycles which allow the reversible formation of the 
oxammonium cation or the hydroxylamine, nitroxides can act catalytically as 
superoxide dismutase mimics [13]. Equally, they may circumvent Fenton derived 
radical pathways by oxidising the metals involved.  Nitroxides have a long history as 
sensitive bio-probes with their paramagnetic signals detected by electron 
paramagnetic resonance (EPR) spectrometry, however one consideration has always 
been biostability, as reduction to the hydroxylamine in vivo leads to slow loss of EPR 
signal [14].  If A-T cells are undergoing high levels of oxidative stress, bioreduction 
should be slowed and nitroxides might be expected to have beneficial impact, thus 
pointing the way towards a means of intervening in the progress of this currently 
untreatable disease. 
 
Here we report the promising results of a study of three water soluble carboxy 
nitroxides on survival rates of A-T cells compared to normal cells when exposed to 
radiation; representing a model for understanding the impact of ROS damage on the 
A-T phenotype.  The carboxy nitroxides all show a significant positive impact, raising 
A-T cell survival towards normal cell responses. The effect is much more significant 
than with vitamin E or Trolox (a water-soluble vitamin E analogue), studied using the 
same cell survival model. 
 
 
MATERIALS AND METHODS 
 
Materials 
The chemical structures for the antioxidants used in this study are shown in 
Figure 1. 
 
CTEMPO (4-carboxy-2,2,6,6-tetramethylpiperidin-1-yloxyl, 2) and 
CPROXYL (3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yloxyl, 3); Tocopherol 
(2,5,7,8-tetramethyl-2-(4’,8’,12’trimethyltridecyl)-6-chromanol) (Vitamin E, 4) and 
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 5); were obtained 
from Sigma-Aldrich Pty Ltd, Australia and were used without further purification. 
Trypan Blue was obtained from Searle Diagnostics, UK and RPMI 1640 growth 
medium from Gibco-BRL. Foetal calf serum was also purchased from Gibco-BRL. 
 
Synthesis of CTMIO and Derivatives 
 
CTMIO, (5-Carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl, 1) 
CTMIO (5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl, 1) was synthesised 
from 5-bromo-1,1,3,3-tetramethylisoindoline (see Scheme 1) via treatment with n-
butyl lithium and carbon dioxide followed by oxidation to the nitroxide in 32% 
overall yield according to methods described previously [15,16]. 
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5-Carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl amide (7) 
 
The novel amide derivative of CTMIO, 5-carboxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl amide (7) was made from the ethyl ester of CTMIO 
via exposure to NH4Cl and base. Thus CTMIO (1) (100 mg, 0.43 mmol) was refluxed 
in ethanol (3 mL) for 24 hours in the presence of catalytic amount of conc. H2SO4. 
The pH was raised with saturated NaHCO3 (10 mL) and extracted with 
dichloromethane (3 x 30mL). Removal of the solvent yielded a yellow solid which 
was recrystallised from H2O/EtOH to give yellow needle-like crystals (83 mg, 74%) 
of the ethyl ester of CTMIO. This material (262 mg, 1.0 mmol) was dissolved in 
methanol/H2O (3mL/2mL), and NH4Cl (160 mg, 3 equiv.) and triethylamine (1.5 g) 
were added. The mixture was refluxed for 72 hours and extracted into 
dichloromethane (3 x 15 mL). The organic layer was dried with Na2SO4, and the 
solvent removed in vacuo. Separation from the starting material by column 
chromatography (4:6 EtOAc/hexane), and evaporation of solvent in vacuo, gave a 
yellow solid. (120 mg, 52%) Mp: 166-168° C; νmax(KBr)/cm-1: 3500-3200 (NH2), 
2976 and 2929 (aryl CH),  1665 (amide C=O), 1618 and 1578 (aryl CH), 1466 and 
1360 (NO). +MS found M+ 233.12918 (0.78ppm from calc. mass for C13H17N2O2). 
1HNMR (in presence of phenylhydrazine): δH  1.48 (12H, s, CH3), 6.14 (2H, broad, 
NH2), 7.37 (1H, d, 7-H), 7.67 (1H, d, 4-H), 7.86 (1H, dd, 6-H). Peaks were present at 
6.83 and 7.25 from phenylhydrazine and derivatives.  
 
 
5-Carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl acetoxymethyl ester (6) 
 
CTMIO (1) (50 mg, 0.22 mmol) was dissolved in 3 mL DMF, and 
acetoxymethyl bromide (0.05 mL, 78 mg, 2.5 equiv.) and triethylamine (0.055 mL, 40 
mg, 2 equiv.) were added. The mixture was refluxed under argon overnight, and then 
allowed to cool to room temperature. Once at room temperature, the reaction mixture 
was diluted with H2O (10 mL) and extracted with dichloromethane (3 x 15mL). The 
organic layer was dried with Na2SO4, and the solvent removed in vacuo. After column 
chromatography (CHCl3), and evaporation of solvent in vacuo, a yellow solid was 
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obtained. (46 mg, 71%). Mp: 76-78° C; νmax(KBr)/cm-1: 2977 and 2927 (aryl CH), 
1765 (sat. ester C=O), 1738 (aryl ester C=O), 1619 and 1594 (aryl CH), 1468 and 
1360 (NO), 1207 (C-O). +MS found M+ 306.13428 (0.44ppm from calc. mass for 
C12H28NO3). 1HNMR (in presence of phenylhydrazine): δH: 1.52 (12H, s, CH3), 2.22 
(3H, s, CH3), 6.18 (2H, s, CH2), 7.44 (1H, d, 7-H), 7.92 (1H, d, 4-H), 8.08 (1H, dd, 6-
H). Peaks were present at 6.90 and 7.32 from phenylhydrazine and derivatives 
Cell Survival Studies 
 
The control cell line C3ABR and A-T cell line AT1ABR were obtained from a 
normal control and an A-T patient, respectively. Epstein-Barr virus was used to 
transform the cells to Lymphoblastoid Cell Lines (LCL) [17]. Cells were cultured in 
RPIM 1640 growth medium, containing 10% foetal calf serum (FCS) and incubated 
at 37°C in a 5% CO2/air atmosphere.  The antioxidants investigated were first 
dissolved in 0.1 mL DMSO to prepare 0.1M stocks. This 0.1M stock solution was 
then diluted with the growth media to make 1 mL of 10 mM antioxidant stock. The 
cell lines of both A-T cells and standard cells were initially divided into four batches 
and diluted so the final concentrations were 100 µM. The first batch was not 
irradiated and not exposed to antioxidant, the second batch was irradiated in the 
absence of the antioxidant, the third batch was not irradiated, but was exposed to the 
antioxidant, and the last batch was irradiated in the presence of the antioxidant.  All 
four aliquots were taken from the cultured medium and counted to ensure consistent 
numbers of cells were present in each aliquot used in the assay. Cells that were 
exposed to the antioxidant studied were exposed for at least six hours prior to the 
irradiation at the significantly lethal dose of 4 Gy. 
 
Trypan Blue solution was used as a visualising media and it consisted of 0.4% 
w/w Trypan Blue in Hanks solution. The dye solution was allowed to settle at least 24 
hours before use. A Trypan blue based visualisation assay using a bright-line 
hemacytometer and an optical microscope was used to determine the numbers of 
viable cells as described previously [18]. 
 
To confirm the nitroxides have minimal toxicity under the conditions used in 
the experiment, cell growth was monitored in the presence of the nitroxides, but 
without exposure to irradiation.  There was no apparent impact on growth rates and on 
numbers of dead cells, indicating no significant cytotoxicity with any of the 
compounds studied. 
 
A cell count of the cell culture was conducted prior to all experiments, in order 
to measure the concentration of cells. Each experiment required dilution to obtain 
approx. 2 × 105 cells/mL.  Appropriate amounts of the cell culture were transferred to 
culture tubes in order to attain approximately 2 × 105 cells/cm3 after dilution to 5 mL. 
Antioxidant stock solution (50 µL of 10 mM) was added to the cell suspension such 
that the final concentration of the antioxidant in the tube after dilution to 5 mL was 
100 µM. 
 
The cell suspensions were irradiated at radiation doses varying from 0 Gy to 4 
Gy at room temperature in a Gammacell 40 Exactor GC-40E, Ontario, Canada at a 
dose rate of 109.6 cGy/min. Results for the 4 Gy irradiation doses are shown.  At 
lower doses similar trends were observed, but decreased lethality gave smaller 
differences between the A-T (AT1ABR) and control (C3ABR) cells. At doses higher 
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than 4 Gy insufficient cells survive to obtain reliable data. After irradiation, the cell 
cultures were diluted to 5 mL, and incubated. To obtain cell counts, 0.1 mL of Trypan 
Blue solution and 0.5 mL of the well-mixed cell suspension were added to a vial. The 
mixture was allowed to sit for 2-3 minutes to enable the dyes to equilibrate. The cells 
were counted every 24 hours after irradiation up to a total time of 4 days.  
 
All counts were conducted in triplicates, to ensure statistical validity of 
results. The cell suspensions were thoroughly mixed before any transfer, to ensure 
equal concentrations. Cell survivability was determined by the ratio of the number of 
living cells in irradiated samples compared to the number of cells surviving in 
samples not exposed to irradiation. Errors were calculated with 95% confidence 
intervals.  
 
Chromosome Aberrations 
 
Cells were treated with or without CTMIO (100 µM) for 4h and then 
irradiated with 1 Gy of γ-radiation under aerobic conditions.  Colcemid (final 
concentration 0.1 µg/ml, Gibco BRL) was added immediately after irradiation, 1-2h 
before harvesting.  The cells were treated for 15 min in 0.075M KCl, fixed in 
methanol-glacial acetic acid (3:1) and the fixed cells were spread on glass slides, air 
dried and stained with Giemsa (Gurr, BDH chemical). Fifty metaphases were 
analyzed for chromosomal aberrations for each sample. 
 
RESULTS 
FIGURE 2  
 
 
 
As observed previously, exposure of A-T cells to radiation revealed that they 
were considerably more sensitive than normal control cells. Although both normal 
and A-T cells demonstrate reduced post-irradiation cell survival, A-T cells display 
significantly poorer growth in the first 24-48 hours, with few surviving past four days. 
This is shown in Figure 2 which comprises a series of plots indicating the normal 
post-irradiation survival profile of healthy cells (Blank Control – solid diamonds) 
compared to A-T cells (Blank A-T – hollow diamonds).  However, when the A-T 
cells were incubated in the presence of the antioxidant CTMIO (100 µM) prior to 
irradiation, survival was enhanced to a level intermediate between A-T and control 
(Figure 2, plot 1 – solid triangles).  Significantly the protective effect towards A-T 
cells was considerably more marked than that observed when the control cells were 
similarly incubated with nitroxide prior to irradiation (Figure 2, plot 1 – hollow 
triangles).  Increasing the concentration of CTMIO to 200 µM did not further enhance 
survival (results not shown).  Two other carboxylated nitroxides, CTEMPO (2) and 
CPROXYL (3), also significantly enhanced the survival of A-T cells post irradiation 
and again the protective effect was only minimal for control irradiated cells under the 
same conditions (Figure 2, plots 2 – solid squares and 3 – solid circles).  
 
EDITOR PLEASE INSERT FIGURE 3 HERE 
 
In order to explore the universality of this effect on A-T cells, we employed 
two other antioxidants: alpha-Tocopherol (4) and Trolox (5). Figure 3 (plot 1) shows 
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the marginal differences in post-irradiation cell survival for both healthy cells and A-
T cells in the presence of alpha-Tocopherol and Trolox.  This low efficacy is 
replicated with the other nitroxides trialed (Figure 3, plot 2).  Interestingly, the 
primary amide nitroxide analogue (7) which is comparable in size and polarity to 
CTMIO, had no significant protective effect on A-T cells. Validation of the 
reproducibility of the assay is demonstrated by repeated separate cell survival assays 
each done in triplicate using CTMIO (Figure 3, plot 3).  
 
Effect of CTMIO (5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl, 1) antioxidant on 
radiation–induced chromosomal aberrations 
 
Table 1: Radiation-induced chromosome aberrations in A-T and control 
cells with and without the antioxidant CTMIO 
 
Number of aberrations 
 
 sb Cb Int ICA/metaphase 
     
C3ABR 48 2 2 1.04 
C3ABR + CTMIO 53 0 1 1.08 
     
ATIABR 150 1 0 3.02 
ATIABR + CTMIO 86 1 0 1.72 
     
 
 
 Sb, chromatid breaks; Cb, chromosome breaks; Int, interchanges; ICA, 
induced chromosome aberrations.  Fifty metaphases were analyzed for each sample. 
C3ABR v ATIABR P<0.0001; ATIABR v ATIABR+CTM P<0.001. (One tailed 
distribution; two sample unequal variance). 
We have previously shown that the number of radiation-induced chromosomal 
aberrations in A-T cells is approximately 3-fold higher than in irradiated control cells 
[17].  Since CTMIO partially corrected against radiation damage as determined by 
cell survival we also investigated whether this compound would reduce the number of 
radiation-induced chromosomal aberrations in A-T cells.  When CTMIO was added to 
control cells prior to radiation the number of aberrations was approximately 1.00, 
comparable to that it unirradiated cells (Table 1).  However, CTMIO reduced 
radiation–induced aberrations from 3.02 to an intermediate value of 1.72 in A-T cells 
a result compatible with the effect on cell survival described above. 
 
 
DISCUSSION 
The three carboxyl nitroxides studied all have a significant impact on the 
survival of the A-T cells. Whilst not reaching the levels of normal cells, the impact of 
these nitroxide antioxidants on A-T cell survival is greater than for the other 
antioxidant systems studied to date (notably vitamin E). The effect on survival is 
further supported by the capacity of the nitroxides to reduce radiation-induced 
chromosome aberrations in A-T cells. These results may represent an important first 
step towards the development of a treatment for A-T and other disorders characterized 
by oxidative stress. 
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The success of the carboxy nitroxides in protecting against cell death and 
induced chromosome aberrations lends support to the concept that A-T cells 
experience high levels of oxidative stress and lack the antioxidant defences of healthy 
cells [6-10]. Importantly the improvement of cell survival by the carboxy nitroxides is 
restricted to the A-T cells, with only minor changes detected in survival rates for the 
irradiated healthy cells.  Nitroxides are recognised radioprotectors [19], however, 
under the concentrations and conditions of these experiments, they are not offering 
much protection to healthy cells. With systems where the cellular antioxidant 
machinery may be flawed however, such as in the case of the A-T cells where 
oxidative stress is increased [6,7], the carboxy nitroxides clearly have a strong effect. 
Thus the preferential protection in A-T cells suggests that radiation damage to DNA is 
not the sole determinant of cell survival outcome, but rather a combination of DNA 
damage and an oxidative stress environment contribute to the sensitivity to radiation. 
 
There have been comparisons of the relative bioactivity of various ring sized 
nitroxides which have shown some variation in the redox properties of five-membered 
versus six-membered ring systems [20]. These structural parameters do not appear to 
have much influence on the role that the nitroxides play in A-T cells. The three 
carboxy nitroxides examined all display similar impact on survival, despite 
representing much of the variation in chemical structures available in the nitroxide 
class of antioxidants. Of much greater influence appears to be the presence of the 
carboxy functional group itself. The primary amide analogue (7) would be expected to 
have comparable polarity and size to CTMIO, yet the impact of 7 on A-T cell survival 
is limited. Equally the lack of efficacy of 7 indicates that under these conditions there 
cannot be significant in situ metabolic conversion of this compound by the A-T cells 
to generate the more potent CTMIO parent.  
 
Metabolic conversion of active esters has been used as a means of delivering 
high levels of nitroxides behind cell membranes in order to enhance imaging 
applications [21].  In this context the rapid intracellular enzymatic hydrolysis of active 
ester moieties, such as that present in 6, converts the membrane-permeable, lipophilic 
ester to the less permeable carboxylate, thereby trapping the nitroxide inside the cell.  
This makes the results of the active ester 6, which displayed very limited influence on 
A-T cell survival rates, very notable.  Either limited enzymatic conversion of this 
compound occurs with 6 in A-T cells, or the mode of action of the carboxy nitroxides 
occurs extracellularly and the polarity of the carboxylate is the prime consideration. 
 
Notably vitamin E in this trial proved much less effective than the carboxy 
nitroxides, despite being a widely recognised antioxidant system. This lower efficacy 
may arise from the possibility that nitroxides can act as catalytic antioxidants by 
involving the oxammonium salt redox couple [22].  Vitamin E on the other hand 
prevents damage by ROS by acting as a hydrogen atom transfer agent.  Without re-
supply of more vitamin E, or in the face of poor enzymatic recovery of the phenoxy 
radical, the antioxidant efficiency must decrease. 
 
To gain insight into the importance of water solubility and carboxylate salt 
structure on the antioxidant effect, the water soluble vitamin E analogue Trolox was 
also investigated using this irradiated A-T cell survival model.  As with treatment 
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with vitamin E, the A-T cells exposed to Trolox again showed little change in 
survivability. 
 
The irradiated A-T cell survival model described here provides a simple, but 
effective means to identify substances which may have an impact on this disease. It is 
important to realise that results in vivo may be markedly different. Significantly 
however we have also shown marked improvement in survival of Purkinje neuronal 
cell cultures from Atm deficient mouse models treated with CTMIO [7] where after 
10 days, treated cells had 60% of wild-type survival, double that recorded in untreated 
Atm-/- cultures. Furthermore, neuronal differentiation in these cultures was improved 
when treated with CTMIO and, most significantly, catalase activity and 4-
nitrotyrosination of proteins, which are indicators of oxidative stress in the 
cerebellum, were markedly decreased in 2 month old Atm deficient mice which had 
been fed CTMIO.  
 
In combination, these results indicate that carboxy nitroxides give insight into 
the important role oxidative stress plays in the disease ataxia-telangiectasia and 
indicate that antioxidants may provide a means of intervening in the progress of this 
disease.  
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Figure 2:  The Impact on A-T cell survival of: CTMIO (5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl, 1), Plot 1; CTEMPO (4-carboxy-
2,2,6,6-tetramethylpiperindinyloxyl, 2), Plot 2; and CPROXYL (3-carboxy-2,2,5,5-tetramethyl-1-pyrolidinyloxyl, 3), Plot 3. Each Plot shows 
untreated A-T cell survival as the bottom curve and treated/untreated normal cell as the top two curves. In each case A-T cells treated with 
nitroxide display enhanced viability. 
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Figure 3 Impact of alpha-Tocopherol (4), Trolox (5) (Plot 1), 5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl acetoxymethyl ester (6) and 5-
carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl amide (7) (Plot 2) on A-T cell survival. Plot 3 shows the reproducibility of the assay where three 
separate experiments conducted triplicate are plotted together.  
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